Compare Inovio Pharmaceuticals Inc (INO) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Okta, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Okta, Inc. trades at $232.13 (market cap $38.50B). The key difference: Okta, Inc. is far larger — about 343.2× Inovio Pharmaceuticals Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Okta, Inc. for 44 Days on average.
| INO | OKTA | |
|---|---|---|
Market Cap | $112.19M | $38.50B |
Volume | 3,201,278 | 2,479,621 |
Sector | Health | Technology |
52-Week High | $2.60 | $232.13 |
52-Week Low | $0.66 | $62.93 |
Typical Hold Time | 43 Days | 44 Days |
Enterprise Value | $83.51M | $36.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Okta (OKTA) trades at $220.21, up 1.01% on the day, with a bullish technical signal from moving averages. The stock has consistently beaten earnings estimates in recent quarters. Revenue growth is strong, reaching $2.61B in 2025, with the company achieving positive net income for the first time. Recent news highlights its strategic focus on AI agent security, with announcements at the Oktane 2026 conference generating positive analyst attention.
The outlook is positive, driven by strong fundamentals and Wall Street's bullish consensus, though high valuation multiples and recent insider selling present risks. The key opportunity lies in Okta's positioning in the growing AI security market, while execution against competition remains a challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
